Ken Griffin Ovid Therapeutics Inc. Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 405,382 shares of OVID stock, worth $531,050. This represents 0.0% of its overall portfolio holdings.

Number of Shares

405,382

Previous 15,600 2498.6%

Holding current value

$531,050

Previous $5,000 10260.0%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$0.32 - $1.73 $129,722 - $701,310	405,382 New	405,382 $518,000
Q1 2025 May 15, 2025	BUY	$0.31 - $0.96 $111,760 - $346,096	360,517 Added 4834.61%	367,974 $114,000
Q4 2024 Feb 14, 2025	BUY	$0.93 - $1.36 $6,935 - $10,141	7,457 New	7,457 $6,000
Q1 2024 May 15, 2024	BUY	$2.72 - $4.04 $370,292 - $549,993	136,137 Added 1215.29%	147,339 $449,000
Q4 2023 Feb 14, 2024	BUY	$2.98 - $3.78 $33,381 - $42,343	11,202 New	11,202 $36,000

Q2 2023 Aug 14, 2023	SELL	$2.53 - $3.89 $68,373 - $105,127	-27,025 Reduced 46.73%	30,812 $101,000
Q1 2023 May 15, 2023	BUY	$1.88 - $2.85 $37,240 - $56,455	19,809 Added 52.09%	57,837 $149,000
Q4 2022 Feb 14, 2023	BUY	$1.43 - $1.89 $54,380 - $71,872	38,028 New	38,028 $70,000
Q1 2022 May 16, 2022	SELL	$2.65 - $3.49 $106,424 - $140,158	-40,160 Reduced 51.21%	38,265 $120,000
Q4 2021 Feb 14, 2022	SELL	$3.13 - $3.73 $58,214 - $69,374	-18,599 Reduced 19.17%	78,425 $251,000
Q3 2021 Nov 15, 2021	BUY	$3.31 - $4.04 $201,615 - $246,080	60,911 Added 168.67%	97,024 $326,000
Q2 2021 Aug 16, 2021	SELL	$3.3 - $4.49 $150,661 - $204,990	-45,655 Reduced 55.83%	36,113 $141,000
Q1 2021 May 17, 2021	BUY	$2.42 - $4.47 $9,590 - $17,714	3,963 Added 5.09%	81,768 $329,000
Q4 2020 Feb 16, 2021	SELL	$2.28 - $6.84 $52,451 - $157,354	-23,005 Reduced 22.82%	77,805 $180,000
Q3 2020 Nov 16, 2020	BUY	$5.39 - $8.24 $424,354 - $648,735	78,730 Added 356.57%	100,810 $579,000
Q2 2020 Aug 14, 2020	BUY	$2.67 - $7.91 $58,953 - $174,652	22,080 New	22,080 $163,000
Q1 2020 May 15, 2020	SELL	$2.03 - $4.35 $77,318 - $165,682	-38,088 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.08 - $5.06 $48,986 - $119,168	23,551 Added 162.01%	38,088 $158,000
Q3 2018 Nov 13, 2018	BUY	$5.6 - $11.0 $81,407 - $159,907	14,537 New	14,537 $0

Others Institutions Holding OVID

# of Institutions

Shares Held

33.1M

Call Options Held

141K

Put Options Held

62.5K

View Full List

About Ovid Therapeutics Inc.

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $92.2M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

More about OVID

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account